PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Clinical and Molecular Hepatology10.3350/cmh.2023.00182023292510-512Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase”Chia-Ming Chu, Yun-Fan Liawhttp://e-cmh.org/upload/pdf/cmh-2023-0018.pdf, http://e-cmh.org/journal/view.php?doi=10.3350/cmh.2023.0018, http://e-cmh.org/upload/pdf/cmh-2023-0018.pdf
Clinical and Molecular Hepatology10.3350/cmh.2023.00442023292513-515Correspondence on Letter regarding “Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune tolerant phase”Jeong-Ju Yoo, Sang Gyune Kimhttp://e-cmh.org/upload/pdf/cmh-2023-0044.pdf, http://e-cmh.org/journal/view.php?doi=10.3350/cmh.2023.0044, http://e-cmh.org/upload/pdf/cmh-2023-0044.pdf
Clinical and Molecular Hepatology10.3350/cmh.2022.03222023292482-495Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phaseJeong-Ju Yoo, Soo Young Park, Ji Eun Moon, Yu Rim Lee, Han Ah Lee, Jieun Lee, Young Seok Kim, Yeon Seok Seo, Sang Gyune Kimhttp://e-cmh.org/upload/pdf/cmh-2022-0322.pdf, http://e-cmh.org/journal/view.php?doi=10.3350/cmh.2022.0322, http://e-cmh.org/upload/pdf/cmh-2022-0322.pdf
Clinical and Molecular Hepatology10.3350/cmh.2023.01322023293812-812Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”Halil Haldun Emirogluhttp://e-cmh.org/upload/pdf/cmh-2023-0132.pdf, http://e-cmh.org/journal/view.php?doi=10.3350/cmh.2023.0132, http://e-cmh.org/upload/pdf/cmh-2023-0132.pdf
Clinical and Molecular Hepatology10.3350/cmh.2023.01352023293820-820Correspondence on Letter regarding “Is liver biopsy essential to identifying the immune tolerant phase of chronic hepatitis B?”Joo Hyun Oh, Dong Hyun Sinnhttp://e-cmh.org/upload/pdf/cmh-2023-0135.pdf, http://e-cmh.org/journal/view.php?doi=10.3350/cmh.2023.0135, http://e-cmh.org/upload/pdf/cmh-2023-0135.pdf
Alimentary Pharmacology & Therapeutics10.1111/apt.159662020525911-912Letter: risk of hepatocellular carcinoma in immune‐tolerant phase of chronic hepatitis BMayur Gattani, Meghraj Ingle, Shamshersingh Chauhan, Saiprasad Ladhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fapt.15966, https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.15966
Alimentary Pharmacology & Therapeutics10.1111/apt.159922020525913-914Letter: risk of hepatocellular carcinoma in immune‐tolerant phase of chronic hepatitis B—authors’ replyHan Ah Lee, Seung Up Kimhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fapt.15992, https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.15992
Journal of Hepatology10.1016/s0168-8278(23)03222-1202378S1107Significant heterogeneity in long-term risks of cirrhosis or hepatocellular carcinoma among a national cohort of U.S. veterans with non-cirrhotic, treatment naïve chronic hepatitis B in the immune tolerant phaseZeyuan Yang, Ramsey C. Cheung, Robert Wonghttps://api.elsevier.com/content/article/PII:S0168827823032221?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168827823032221?httpAccept=text/plain
Journal of Hepatology10.1016/s0168-8278(87)80353-719875S136Clinical, serological and histologic follow-up of chronic HBV and HDV hepatitishttps://api.elsevier.com/content/article/PII:S0168827887803537?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0168827887803537?httpAccept=text/plain
Alimentary Pharmacology & Therapeutics10.1111/apt.1597320205261093-1093Letter: fatty liver disease could have been a confounding factor for phase change in patients with chronic hepatitis B in the immune tolerant phaseBo Wan, Ruanqin Chen, Han Linhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.15973